Kera Capital Partners Inc. Purchases Shares of 18,643 Avantor, Inc. (NYSE:AVTR)

Kera Capital Partners Inc. acquired a new position in shares of Avantor, Inc. (NYSE:AVTRFree Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 18,643 shares of the company’s stock, valued at approximately $393,000.

Several other large investors also recently made changes to their positions in AVTR. State Street Corp boosted its holdings in Avantor by 58.0% in the third quarter. State Street Corp now owns 22,368,244 shares of the company’s stock worth $578,666,000 after acquiring an additional 8,206,695 shares in the last quarter. Janus Henderson Group PLC grew its position in Avantor by 18.2% in the 3rd quarter. Janus Henderson Group PLC now owns 17,692,705 shares of the company’s stock valued at $457,710,000 after purchasing an additional 2,719,615 shares during the period. Geode Capital Management LLC grew its position in Avantor by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 11,150,788 shares of the company’s stock valued at $287,791,000 after purchasing an additional 739,667 shares during the period. 1832 Asset Management L.P. raised its holdings in Avantor by 1,634.9% during the second quarter. 1832 Asset Management L.P. now owns 8,530,118 shares of the company’s stock worth $180,839,000 after buying an additional 8,038,451 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Avantor by 653.0% during the third quarter. The Manufacturers Life Insurance Company now owns 6,174,736 shares of the company’s stock worth $159,740,000 after buying an additional 5,354,678 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Avantor Price Performance

AVTR opened at $22.14 on Friday. Avantor, Inc. has a fifty-two week low of $19.59 and a fifty-two week high of $28.00. The firm has a 50-day moving average of $21.45 and a 200 day moving average of $23.35. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The firm has a market cap of $15.07 billion, a P/E ratio of 48.13, a PEG ratio of 3.42 and a beta of 1.28.

Analyst Upgrades and Downgrades

Several research firms have recently commented on AVTR. UBS Group reissued a “neutral” rating and set a $25.00 target price (down from $29.00) on shares of Avantor in a research report on Friday. Barclays lowered their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $34.00 target price on shares of Avantor in a research report on Thursday, September 26th. Wells Fargo & Company lowered their price target on Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, October 28th. Finally, Robert W. Baird cut their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Avantor presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.38.

Check Out Our Latest Stock Report on Avantor

About Avantor

(Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

Further Reading

Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTRFree Report).

Institutional Ownership by Quarter for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.